Cartesian Therapeutics
RNAC
68 hedge funds and large institutions have $119M invested in Cartesian Therapeutics in 2024 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 9 reducing their positions, and 11 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 9
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
8% more capital invested
Capital invested by funds: $110M → $119M (+$9.13M)
6% more funds holding
Funds holding: 64 → 68 (+4)
2.84% less ownership
Funds ownership: 28.75% → 25.91% (-2.8%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.78M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.77M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$1.86M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.73M |
| 5 |
6CM
683 Capital Management
New York
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.68M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.22M |
| 3 |
YU
Yale University
New Haven,
Connecticut
|
-$1.61M |
| 4 |
AC
Armistice Capital
New York
|
-$1.59M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.23M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Acadian Asset Management
Boston,
Massachusetts
| – | -$28K | -1,761 | Closed |
|
|
AAP
77
Arax Advisory Partners
Denver,
Colorado
| – | -$194 | -12 | Closed |
|
RNAC Hedge Fund Activity: Q4 2024 in Review
68 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2024, worth a combined $119M — up 8.3% from $110M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new RNAC positions and 11 closed out — a net gain of 4 holders — while 30 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $4.78M. The largest seller was Fidelity Investments, cutting an estimated $8.68M.
- 68 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2024, up from 64 in Q3 2024.
- Funds reported $119M of Cartesian Therapeutics stock for Q4 2024, up 8.3% quarter-over-quarter.
- 15 funds opened new Cartesian Therapeutics positions in Q4 2024 and 11 closed out, a net change of +4 holders.
- The largest Cartesian Therapeutics buyer in Q4 2024 was BlackRock, an estimated $4.78M added.
- The largest Cartesian Therapeutics seller in Q4 2024 was Fidelity Investments, an estimated $8.68M sold.
Based on aggregated 13F filings for Q4 2024.